Use of mast cell stabilizer for the treatment of heart failure with

Heart failure with preserved ejection fraction (HFpEF) which results from diastolic dysfunction is a growing epidemiologic problem. However, the […]

Method for predicting the response to tnf inhibitors

Rheumatoid arthritis (RA) is the most prevalent chronic autoimmune inflammatory rheumatism. Its pathophysiology is largely dependent on TNF. Severe RA […]

Methods for detecting the presence of pemphigus-specific

Pemphigus is a group of rare autoimmune diseases that causes blistering of the skin and mucous membranes, and includes pemphigus vulgaris (PV) and […]

Method for predicting survival time in patients suffering from cancer

The inventors found that metabolic gene signatures of human pan-tumor associated myeloid cells correlate with patient survival and cancer cell mitotic […]

Use of cd160 as a biomarker in acute myeloid leukemia

Natural killer (NK) cells are innate cytotoxic lymphoid cells (ILCs) involved in the killing of infected and tumor cells. Several NK cell subsets have […]

Use of slamf1 as a biomarker in colorectal cancer

Innate lymphoid cells (ILCs) are tissue-resident lymphocytes that differ from conventional T lymphocytes in having no antigen-specific receptors. ILCs […]

Bile salts bactosensor and use thereof for diagnostic and therapeutic

Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are […]

Methods for detecting the presence of coronavirus-specific antibodies

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The viral genome is 26–32 kilobases in length. In late December […]

New serological marker for the latent form of toxoplasmosis

In the present invention, inventors report the characterization of BCLA (Brain Cyst Load-associated Antigen), a protein exclusively expressed during […]

Methods for discontinuing a treatment with a tyrosinekinase inhibitor

The present invention relates to a method for discontinuing a treatment with a TKI by determining the number and/or frequency of innate CD8(+) T-cells […]